<DOC>
	<DOCNO>NCT00080665</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy docetaxel work different way stop tumor cell divide stop grow die . Imatinib mesylate may stop growth tumor cell block enzymes necessary growth . Giving docetaxel imatinib mesylate may kill tumor cell . PURPOSE : This phase I trial study side effect best dose docetaxel give together imatinib mesylate treat patient locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Docetaxel Imatinib Mesylate Treating Patients With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety profile , maximum tolerate dose , recommend phase II dose docetaxel administer imatinib mesylate patient locally advance metastatic breast cancer . Secondary - Determine pharmacokinetic profile regimen patient . - Determine potential effect regimen CYP3A4 activity docetaxel metabolism patient . - Correlate docetaxel imatinib mesylate exposure ( utilizing total unbound docetaxel imatinib mesylate plasma concentration ) drug response ( e.g. , pharmacodynamic effect , drug toxicity , response ) patient . - Determine response rate , duration response , time treatment failure patient treat regimen . - Correlate proteomic profile change serum tumor burden response patient treat regimen . - Correlate pharmacokinetic parameter , tissue expression specific receptor tyrosine kinase ( e.g. , c-Kit , platelet-derived growth factor receptor [ PDGFR ] , phosphorylated PDGFR ) paraffin block , pharmacodynamic assay antitumor activity regimen patient . OUTLINE : This open-label , dose-escalation study docetaxel . Patients receive docetaxel IV 1 hour day 1 , 8 , 15 oral imatinib mesylate ( STI571 ) day 8-28 course 1 day 1-28 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity* . Patients stable respond disease least 2 course therapy may discontinue docetaxel continue therapy single-agent STI571 disease progression . NOTE : *Patients experience excessive docetaxel-related toxicity complete least 2 full course may continue single-agent STI571 absence disease progression excessive STI571-related toxicity . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional cohort 6-12 patient receive treatment MTD . Patients follow 30 day . PROJECTED ACCRUAL : Approximately 18-30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Stage IIIB , IIIC , IV disease Measurable evaluable disease Stable brain metastasis allow provide prior surgery radiotherapy complete 90 day ago No document suspected leptomeningeal disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic Granulocyte count ≥ 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ upper limit normal ( ULN ) Meets 1 follow criterion AST ALT AND alkaline phosphatase : AST ALT ≤ ULN AND alkaline phosphatase ≤ 5 time ULN AST ALT ≤ 2.5 time ULN AND alkaline phosphatase ≤ ULN AST ALT ≤ 1.5 time ULN AND alkaline phosphatase ≤ 2.5 time ULN No known acute chronic liver disease ( e.g. , chronic active hepatitis cirrhosis ) Renal Creatinine ≤ 1.5 mg/dL Cardiovascular No New York Heart Association class III IV heart disease No congestive heart failure No myocardial infarction within past 6 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month study participation No primary malignancy except malignancy clinically insignificant AND require active intervention No concurrent severe and/or lifethreatening medical disease No significant history noncompliance medical regimen inability grant reliable informed consent PRIOR CONCURRENT THERAPY : Biologic therapy At least 14 day since prior systemic trastuzumab ( Herceptin® ) No concurrent trastuzumab No concurrent biologic therapy primary malignancy Chemotherapy Prior taxane therapy , include docetaxel , adjuvant metastatic setting allow At least 21 day since prior systemic chemotherapy ( 14 day weekly oral chemotherapy 42 day nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy At least 14 day since prior systemic hormonal therapy No concurrent antiestrogen therapy No concurrent routine systemic corticosteroid therapy except premedication chemotherapy Concurrent megestrol allow appetite stimulant Radiotherapy See Disease Characteristics At least 14 day since prior radiotherapy No prior radiotherapy site measurable/evaluable disease unless new evidence postradiotherapy disease progression No concurrent radiotherapy Surgery See Disease Characteristics More 2 week since prior major surgery Other Recovered prior therapy At least 14 day since prior daily weekly systemic investigational treatment No concurrent warfarin full anticoagulation Concurrent lowdose warfarin ( e.g. , 1 mg/day ) allow prophylaxis central venous access No concurrent treatment follow : Phenobarbital Phenytoin Carbamazepine Barbiturates Rifampin Hypericum perforatum ( St. John 's wort ) No concurrent therapy primary malignancy No concurrent investigational drug systemic therapy No concurrent bisphosphonates unless start study therapy No concurrent grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>